BIO 106 - Boostimmune
Alternative Names: BIO-106 - BoostimmuneLatest Information Update: 03 Oct 2023
At a glance
- Originator Boostimmune
- Class Antibodies; Antineoplastics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
Most Recent Events
- 23 Aug 2023 Early research in Cancer in China (Parenteral), prior to August 2023 (Boostimmune pipeline, August 2023)